Universal Cells Corp. has proprietary technology to suppress cell rejection due to leukocyte type antigen (HLA) incompatibility, andthus owns a universal donor cell technology, capable of creating cellular medical products that can be used for the treatment of all patients. Astellas’ Institute for Regenerative Medicine (AIRM) and Universal Cells cooperated on one indication since October 2017 through an exclusive license agreement. With this acquisition, Astellas Pharma will be able to combine its fundamental technology for acquiring functional cells differentiated from pluripotent stem cells and the universal donor cell technology for creating pluripotent stem cells with suppressed immune rejection.

Astellas Pharma news release, February 14, 2018